NCT01529424

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 89 (actual)
• Sponsor: Ionis Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.

Conditions

• Hypertriglyceridemia

Interventions

Type	Name	Description
DRUG	ISIS apoC-III Rx	Dose 1
DRUG	ISIS apoC-III Rx	Dose 2
DRUG	ISIS apoC-III Rx	Dose 3
DRUG	Placebo	Dose 1
DRUG	Placebo	Dose 2
DRUG	Placebo	Dose 3

Timeline

• Start date: 2012-02-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2012-02-08
• Last updated: 2022-01-27

Locations

7 sites across 2 countries: United States, Canada